Adjuvant

BioSante Pharmaceuticals presents positive results of study for new mucosal vaccine

Published in Vaccine Weekly, July 31st, 2002

BioSante Pharmaceuticals, Inc., (BISP) announced that successful results of a preclinical trial demonstrating the effectiveness of its calcium phosphate nanoparticulate (CAP) vaccine adjuvant and delivery system (Bio-Vant) as a mucosal vaccine adjuvant were presented at the International Congress of Mucosal Immunology in Orlando, Florida.

"These study results further demonstrate the potential of our proprietary CAP technology to allow oral or intranasal formulations of vaccines that previously had to be administered by injection," said Stephen M. Simes, president and chief executive officer of BioSante. "This is not only more convenient and less painful than...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-07-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry